Facebook Pixel Healing an Ailing MedTech Talent Ecosystem | BioSpectrum Asia – business – Lesen Sie diese Geschichte auf Magzter.com
Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

Healing an Ailing MedTech Talent Ecosystem

BioSpectrum Asia

|

BioSpectrum Asia April 2025

The Asia-Pacific (APAC) region represents a critical landscape for the future of medical technology. However, a thriving medical technology sector needs people skilled in engineering, product development and manufacturing. With advances in artificial intelligence (AI) and robotic surgeries driving a big transformation and creating new opportunities, it is also deepening the skills gap many workers face. Let's take a closer look at these gaps and the solutions that are emerging to address those gaps.

- Vrushti Kothari

Healing an Ailing MedTech Talent Ecosystem

The demand for personalised and efficient healthcare is on the rise and the medical technology (medtech) industry is booming within the APAC region. But at the same time, the region is faced with an ageing population and a growing burden of disease, exacerbated by limited healthcare infrastructure and manpower.

Further, the region is witnessing accelerated adoption of artificial intelligence (AI), robotics, 3D printing, and smart diagnostics, reshaping healthcare delivery and patient outcomes. Both the public and private sectors across APAC countries are investing in the growing adoption of new technologies to strengthen the MedTech sector.

If we look closely, individual countries within the APAC region have distinct technological strengths and capabilities. For instance, China and India stand out for their vast technical talent pools, while Japan and South Korea are notable for having a large pool of users for AI-enabled solutions; and Singapore and Australia are recognised for their well-established healthcare data infrastructure and strong capabilities in AI development.

imageHowever, workers within the medtech often lack access to the necessary training or educational resources required to adopt the new skills. This digital divide has led to a growing demand for scalable and accessible upskilling initiatives. Thus, the medtech sector within the APAC region must prepare their workforces for a technology-driven future in order to realise economic growth, social equity and innovation, to avoid wage gaps, trade imbalances and security threats.

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India–EU FTA Paves Way for Expanded Healthcare Trade

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India

In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Women's Health Surge in APAC

The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.

time to read

6 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer

Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Daiichi Sankyo names Dr John Tsai as Global Head of R&D

Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"

King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

SEOUL'S RISKY DRUG PRICING RESET

Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.

time to read

2 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules

Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9

US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

China revises drug administration regulations to spur innovation

China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.

time to read

1 min

BioSpectrum Asia March 2026

Listen

Translate

Share

-
+

Change font size